Zealand Pharma A/S (CPH:ZEAL)
Denmark · Delayed Price · Currency is DKK 291.40
-5.90 (-1.98%)
Jul 21, 2026, 11:09 AM CET
Zealand Pharma Cash Flow Statement
Financials in millions DKK. Fiscal year is January - December.
Millions DKK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 6,396 | 6,455 | -1,079 | -703.74 | -1,202 | -1,018 |
Depreciation & Amortization | 31.41 | 27.37 | 25.85 | 25.09 | 117.96 | 42.95 |
Stock-Based Compensation | 124.89 | 115.89 | 87.03 | 61.43 | 52.29 | 53.5 |
Other Adjustments | 232.13 | 253.47 | -93.78 | 128.16 | 137.72 | -52.13 |
Change in Receivables | -29.26 | -108.95 | -3.45 | -18.61 | 33.11 | -64.49 |
Changes in Inventories | - | 10.7 | -2.76 | 9.34 | 18.22 | -52.77 |
Changes in Accounts Payable | -254.86 | -178.34 | 89.92 | 39.84 | 21.55 | -49.06 |
Changes in Accrued Expenses | - | - | - | -2.16 | -22.52 | - |
Changes in Income Taxes Payable | -567.37 | -21.31 | 6.54 | 11.3 | 9.28 | -41.63 |
Changes in Unearned Revenue | 97.34 | 65.34 | - | - | -67.58 | -30.19 |
Changes in Other Operating Activities | -285.74 | -87.24 | 38.68 | 23.69 | -40.21 | - |
Operating Cash Flow | 6,361 | 6,532 | -930.82 | -425.67 | -942.31 | -1,212 |
Capital Expenditures | -36.91 | -33.37 | -10.05 | -11.24 | -11.71 | -22.13 |
Purchases of Intangible Assets | -34.4 | -35.71 | -3.1 | -12.51 | - | - |
Purchases of Investments | -15,565 | -14,329 | -11,431 | -2,160 | -700.48 | 0 |
Proceeds from Sale of Investments | 12,718 | 12,150 | 4,138 | 1,090 | 887.06 | 0 |
Proceeds from Business Divestments | - | - | - | - | 106.39 | 0 |
Other Investing Activities | - | - | - | - | - | 4.01 |
Investing Cash Flow | -2,920 | -2,249 | -7,307 | -1,094 | 281.26 | -18.12 |
Long-Term Debt Issued | - | - | 369.87 | - | - | 647.91 |
Long-Term Debt Repaid | -24.83 | -20.16 | -16.44 | -543.43 | -449.81 | -14.72 |
Net Long-Term Debt Issued (Repaid) | -24.83 | -20.16 | 353.43 | -543.43 | -449.81 | 633.19 |
Issuance of Common Stock | 46.61 | 49.15 | 8,523 | 1,564 | 1,085 | 775.05 |
Repurchase of Common Stock | - | -407.17 | -351.83 | -41.6 | - | -28.59 |
Net Common Stock Issued (Repurchased) | 46.61 | -358.02 | 8,172 | 1,522 | 1,085 | 746.46 |
Other Financing Activities | - | - | -236.58 | -71.91 | -47.35 | -46.9 |
Financing Cash Flow | -385.39 | -378.18 | 8,288 | 907.01 | 587.5 | 1,333 |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | 16.26 | -54.74 | 6.23 | -7.24 | 13.68 | 66.22 |
Net Cash Flow | 3,056 | 3,905 | 51.16 | -612.69 | -73.55 | 102.66 |
Free Cash Flow | 6,324 | 6,499 | -940.87 | -436.91 | -954.02 | -1,234 |
Free Cash Flow Growth | -2.69% | - | - | - | - | - |
FCF Margin | 68.44% | 70.52% | -1500.80% | -127.46% | -917.45% | -1136.94% |
Free Cash Flow Per Share | 88.08 | 90.83 | -14.16 | -7.72 | -20.65 | -28.79 |
Levered Free Cash Flow | 5,355 | 6,218 | -577.24 | -1,151 | -1,627 | -537.79 |
Unlevered Free Cash Flow | 6,350 | 7,285 | -1,129 | -480.52 | -817.7 | -941.23 |